Showing results (21-30 of 216) with videos related to

Sort By:
Pageof 22
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancerKatsutoshi Sekine, Shintaro Kanda, Yasushi Goto, et al.
Japanese Journal of Clinical Oncology|February 16, 2013
Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung diseaseShinji Nakamichi, Kaoru Kubota, Hidehito Horinouchi, et al.
Japanese Journal of Clinical Oncology|April 19, 2017
Efficacy and safety of osimertinib in a Japanese compassionate use programYutaka Fujiwara, Yasushi Goto, Shintaro Kanda, et al.
BMJ Case Reports|June 21, 2011
Organising pneumonia after near-drowningNoboru Uchiyama, Rika Suda, Sayaka Yamao, et al.
Thoracic Cancer|August 15, 2025
Effects of Sarcopenia on the Outcomes and Safety of Chemoradiotherapy Followed by Durvalumab for the Treatment of Patients With Locally Advanced Non-Small Cell Lung CancerKentaro Tamura, Hidehito Horinouchi, Mototaka Miyake, et al.
Plos One|October 5, 2019
Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung diseaseChihiro Udagawa, Hidehito Horinouchi, Kouya Shiraishi, et al.
Respiratory Investigation|March 4, 2025
A phase 1 study of pembrolizumab plus ipilimumab as first-line treatment in Japanese patients with advanced non-small-cell lung cancerNaoyuki Nogami, Shigeki Umemura, Toshiyuki Kozuki, et al.
Cancer Science|November 9, 2010
Innovator and generic cisplatin formulations: comparison of renal toxicityIkuo Sekine, Kaoru Kubota, Yosuke Tamura, et al.
Cancer Science|April 12, 2020
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancerShintaro Kanda, Yuichiro Ohe, Yasushi Goto, et al.
International Journal of Radiation Oncology, Biology, Physics|December 25, 2015
Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the HeterogeneityHidehito Horinouchi, Yasushi Goto, Shintaro Kanda, et al.
Pageof 22